5:25 PM
 | 
Sep 12, 2013
 |  BC Extra  |  Top Story

BMS's Yervoy misses in prostate cancer

Bristol-Myers Squibb Co. (NYSE:BMY) said IV Yervoy ipilimumab following single-dose radiotherapy missed the primary endpoint of improving median overall survival (OS) vs. placebo following single-dose radiotherapy in the Phase III CA184-043...

Read the full 142 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >